Postoperative radiotherapy after prostatectomy--a review.

Area of Science:

• Oncology
• Radiation Oncology
• Urologic Oncology

Background:

• The use of postoperative irradiation for prostate adenocarcinoma following radical prostatectomy is a subject of ongoing debate.
• Limited high-quality evidence exists due to the absence of randomized controlled trials.

Purpose of the Study:

• To conduct a comprehensive literature review on the efficacy and safety of postoperative radiotherapy in managing prostate adenocarcinomas.
• To analyze existing data regarding survival outcomes, optimal timing, risk factors, dosage, techniques, and side effects.

Main Methods:

• A systematic review of 417 English-language articles published between 1990 and 2002.
• Articles were evaluated for their findings on survival, irradiation timing, risk stratification, dose/technique, and adverse events.

Main Results:

• Postoperative radiotherapy shows potential for enhancing local tumor control, particularly in pT3/4 prostate cancers with seminal vesicle involvement, positive surgical margins, high Gleason scores, or elevated postoperative PSA levels.
• No significant improvement in overall survival has been demonstrated.
• Severe side effects are reported infrequently, but can occur.

Conclusions:

• While definitive conclusions on survival benefits are lacking, postoperative radiotherapy can improve local control in select prostate cancer patients.
• Optimal timing for adjuvant or salvage treatment is 3-6 months post-surgery, with a recommended dose of 65-70 Gy to the prostate bed.
• Improved local control is observed in patients with positive margins or local relapse, especially with lower PSA levels (<1-2 ng/mL).